发明公开
EP1692502A2 USE OF THE LIPOXIN RECEPTOR, FPRL1, AS A TOOL FOR IDENTIFYING COMPOUNDS EFFECTIVE IN THE TREATMENT OF PAIN AND INFLAMMATION
审中-公开
使用本LIPOXINREZEPTORS FPRL1作为标识的疼痛和炎症的活性化合物的治疗手段
- 专利标题： USE OF THE LIPOXIN RECEPTOR, FPRL1, AS A TOOL FOR IDENTIFYING COMPOUNDS EFFECTIVE IN THE TREATMENT OF PAIN AND INFLAMMATION
- 专利标题（中）： 使用本LIPOXINREZEPTORS FPRL1作为标识的疼痛和炎症的活性化合物的治疗手段
-
申请号： EP04810415.2申请日： 2004-11-04
-
公开(公告)号： EP1692502A2公开(公告)日： 2006-08-23
- 发明人: NASH, Norman , SCULLY, Audra, L. , GARDELL, Luis , OLSSON, Roger , GUSTAFSSON, Magnus
- 申请人： Acadia Pharmaceuticals Inc.
- 申请人地址： 3911 Sorrento Valley Blvd. San Diego, CA 92121 US
- 专利权人： Acadia Pharmaceuticals Inc.
- 当前专利权人： Acadia Pharmaceuticals Inc.
- 当前专利权人地址： 3911 Sorrento Valley Blvd. San Diego, CA 92121 US
- 代理机构： Plougmann & Vingtoft A/S
- 优先权： US518476P 20031107; US519085P 20031110; US592926P 20040730
- 国际公布： WO2005047899 20050526
- 主分类号： G01N33/50
- IPC分类号： G01N33/50
摘要：
Disclosed herein are compounds that selectively activate the FPRL1 receptor. Further disclosed are methods of alleviating inflammatory responses by regulating key steps in leukocyte trafficking and preventing neutrophil-mediated tissue damage by administering to a subject a therapeutically effective amount of the compounds disclosed herein. In addition, methods of modulating, or specifically agonizing, the FPRL1 receptor by administering an effective amount of the compounds disclosed herein are provided.
信息查询
IPC分类:
